Navigation Links
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Date:8/16/2011

generation (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.  Bayer submitted an application for marketing authorization in Europe in wet AMD in June 2011.

Bayer HealthCare will market EYLEA™ (aflibercept injection) outside the United States, where the companies will share equally the profits from any future sales of EYLEA.  Regeneron maintains exclusive rights to EYLEA in the United States.

Conference Call InformationLeonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, and other members of senior management will host a conference call to discuss the extension of the review period for EYLEA BLA for the treatment of patients with wet AMD, as well as other corporate matters.  The interactive call will be held on August 17, 2011 at 8:30 a.m. Eastern Time and can be accessed live through the Regeneron website at www.regeneron.com on the Investor Relations page.  The call, including the question and answer session, can also be accessed by dialing:

Domestic Dial-in Number: (888) 660-6127

International Dial-in Number: (973) 890-8355

Participant Passcode: 92316573

An archived version of the conference call will be available for 30 days on the company's website at www.regeneron.com on the Investor Relations page.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
6. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
7. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Anesiva Announces Second Quarter 2008 Financial Results and Update
10. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
11. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... 16, 2015 The Council for ... prestigious 2015 Borlaug CAST Communication Award goes to ... Tuskegee University in Alabama. Award nominees must demonstrate ... presentations; and/or the use of television, radio, or ... areas. As a specialist in the field of ...
(Date:4/16/2015)... Md. , April 16, 2015  RegeneRx ... today announced its U.S. joint venture with G-treeBNT ... a phase 3 clinical trial for the orphan ... confirmatory trial for dry eye syndrome (DES) in ... preservative-free eye drops, RGN-259/GBT201, this year.  Each of ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... of Directors,has elected Jean-Marc Huet senior vice president ... this role, Mr. Huet will be,responsible for directing ... the global financial operations of the organization and ...
... phase II study of 20 patients reported in ... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) ... results of a limited phase II study of ... of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60,years ...
... of electrical and computer engineering at the University ... Career Development Award from the National Science Foundation ... evolution of electronics known as spintronics. , This ... property of electrons to produce electronics ranging from ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... 2013 Scientists have identified higher levels of a receptor ... that may serve as a new drug target for the ... in EMBO Molecular Medicine , show that elevated levels ... transfection", are associated with a lower likelihood of survival for ...
... German . To write ... fingers to tap on the keyboard. Neuronal cells with their cable-like extensions, ... to move. The axonal signal speed can be to up to 100m/s ... scientists assumed that axonal signal conduction is by and large digital: either ...
... Case Western Reserve University School of Medicine have identified ... from changing its molecular shape into the abnormal form ... July 18 issue of Cell Reports , offers ... until now has always proved fatal. Prion diseases ...
Cached Biology News:Haste and waste on neuronal pathways 2Haste and waste on neuronal pathways 3Haste and waste on neuronal pathways 4New approach to protecting prion protein from altering shape 2
... Rabbit polyclonal antibody to human XAB2 (amino ... first identified through its interaction with XPA. ... fraction of XAB2 interacts with the transcription-coupled ... as with RNA polymerase II. Microinjection experiments ...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
... Kits are based on well-established periodate ... consistent and reproducible. This kit contains ... protein or antibody, including ready-to-use buffers ... Activated HRP is supplied ready-to-use and ...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
Biology Products: